Given the fact that the Q2 report has a 478M revenue from sale of a stake in another company, it seems that the real P/E is way higher than stated going forward. Would you recalculate the P/E without this amount when comparing it with other companies. The current P/E is 22, already kinda expensive when c/w other biotechs. How would one figure out the true P/E?
Leave a Reply